Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

Furthermore, the analysis of publicly available datasets of patients treated with trastuzumab, a monoclonal antibody used ... including highly robust antibody-dependent cell mediated cytotoxicity ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...